1. South Korea Stocks

  2. •

    Producer manufacturing

  3. •

    Industrial machinery
TELCON RF PHARMACEUTICAL. Inc.

TELCON RF PHARMACEUTICAL. Inc.

KKRX:200230
2,090.00
KRW
-35.00
(-1.65%)
-4,720.84EPS
17.34BMarket Cap
TELCON RF PHARMACEUTICAL. Inc.
KRX:200230
(Korea Stock Exchange)

Recent

price

2,090.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
37,340.47
38,275.11
15,321.9
14,992.94
15,856.67
20,245.98
17,087.25
10,443.41
11,615.53
7,077.46
8,755.29
8,627.98
8,998.41
10,806.26
Revenue per Share
6,316.35
4,391.52
186.92
-2,129.71
-6,335.22
-4,825.55
-17,846.46
-12,886.12
-7,090.06
-10,702.48
3,353.46
-5,997.25
-2,388.3
-3,057.56
Basic EPS, GAAP
9,263.06
313.54
1,069.88
-18,886.35
-21,798.76
-6,105.64
1,280.78
-571.69
-1,894.54
-744.32
-731.28
-855.86
280.76
8.23
Free Cash Flow per Basic Share
800.63
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
12,081.76
23,194.79
23,615.38
30,105.64
39,927.24
50,435.93
35,360.37
28,138.32
28,758.49
20,881.52
24,277.35
18,583.97
15,836.3
10,255.92
Book Value per Share
11,978.29
23,016.58
23,475.71
15,069.84
14,982
34,396.11
24,149.03
18,232.99
20,609.41
14,953.57
19,318.17
14,379.85
13,466.82
7,316.63
Tangible Book Value per Share
1
2
2
2
3
3
3
3
3
4
4
4
5
6
Basic Weighted Avg Shares
46,639
58,756
28,543
29,840
41,149
57,708
52,478
33,141
37,841
27,830
36,307
37,865
43,162
61,784
Sales/Revenue/Turnover
21.14
13.73
-1
-27.14
-30.88
-13.65
5.96
-6.31
-7.24
-14.6
2.66
-0.19
1.66
0.62
Operating Margin (%)
225
428
542
1,330
2,168
4,116
4,432
4,397
4,200
4,281
4,244
4,507
4,824
5,904
Depreciation Expense
7,889
6,741
348
-4,239
-16,440
-13,755
-54,810
-40,893
-23,098
-42,084
13,906
-26,320
-11,456
-17,481
Net Income, GAAP
21.93
20.59
44.84
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
16.92
11.47
1.22
-14.2
-39.95
-23.83
-104.44
-123.39
-61.04
-151.22
38.3
-69.51
-26.54
-28.29
Profit Margin (%)
19,080
39,375
37,514
14,418
-18,574
-712
17,990
-50,664
-22,756
-11,202
-1,935
-43,709
11,475
-8,336
Working Capital
- -
- -
- -
9,242
4,168
- -
1,758
2,574
1,301
728
403
590
1,433
3,819
LT Debt
22,507
43,209
43,992
82,362
134,496
155,452
113,125
91,475
106,608
84,135
104,945
83,135
108,818
99,484
Total Equity
- -
17.8
-0.35
- -
- -
- -
- -
- -
- -
- -
0.79
- -
- -
- -
Return on Invested Capital (%)
- -
19.37
0.8
- -
- -
- -
- -
- -
- -
- -
11.73
- -
- -
- -
Return on Capital (%)
- -
20.52
0.8
-7.79
-19.05
-10.51
-41.23
-40.25
-23.34
-44.14
14.75
-28.11
-11.97
-25.21
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
32,835
38,513
59,328
LT Borrowings
- -
- -
700
LT Finance Leases
1,433
1,310
3,119
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
62,827
56,524
17,342

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
57,735
63,847
71,665
Cash, Cash Equivalents & STI
32,125
30,842
36,578
Accounts Receivable, Net
8,100
8,291
11,701
Inventories
5,123
4,973
15,775
Total Current Liabilities
46,259
51,500
80,001
Payables & Accruals
- -
- -
- -
ST Debt
32,835
38,513
59,328
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15%
6.06%
30.89%
Free Cash Flow
-219.42%
15.85%
-135.85%
Net Income, GAAP
-121.28%
-88.02%
-56.48%
Sales/Revenue/Turnover
7.32%
7.29%
13.99%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,036
8,827
7,163
13,839
37,865
2025
9,984
10,030
9,825
13,322
43,162
2026
9,700
28,937
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-16,902.91
-22,779.83
6,766.55
-2,736.83
-5,997.25
2025
-1,094.51
-1,345.22
-1,382.63
1,437.83
-2,388.3
2026
-1,673.68
-1,949
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Applied Materials, Inc. (NASDAQ:AMAT)
Oklo Inc. (NYSE:OKLO)
Lam Research Corporation (NASDAQ:LRCX)
Tokyo Electron Ltd. (TSE:8035)
Welspun Corp Limited (NSE:WELCORP)
Symbotic Inc. (NASDAQ:SYM)
Business
TELCON RF PHARMACEUTICAL. Inc. operates in two distinct business areas: radio frequency (RF) communications equipment and pharmaceuticals. The company engineers, produces, and distributes a global range of RF coaxial connectors, couplers, distributors, arresters, and integrated cable assemblies utilized in wireless communication systems, including 5G, as well as in automotive, medical, and military sectors. Furthermore, its pharmaceutical and biotechnology division manufactures and supplies various finished medicinal products, such as liquids, tablets, pills, and capsules, which now generate the majority of its overall revenue. Established in 1999 as Telcon Co., Ltd., the company maintains its headquarters in Yongin-si, South Korea.